The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative
- PMID: 33447768
- PMCID: PMC7803074
- DOI: 10.1016/j.ijchy.2020.100042
The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative
Abstract
Background: It is unknown whether population based single assessment of cardiovascular disease (CVD) risk and feedback to individuals and general practitioners results in initiation of preventive cardiovascular pharmacotherapy in those at risk.
Methods: The population based cohort study Lifelines was linked to the IADB.nl pharmacy database to assess information on the initiation of preventive medication (N = 48,770). At the baseline visit, information on cardiovascular risk factors was collected and reported to the participants and their general practitioners. An interrupted-time-series-analysis was plotted, in which the start year of blood pressure and lipid lowering medication was displayed in years before or after the baseline visit. Subsequently, predictors of the initiation of pharmacotherapy were determined and possible reduction in cardiovascular events that could be achieved by optimal treatment of individuals at risk.
Results: Before the Lifelines baseline visit, 34% (out of 1,527, 95% Confidence interval (CI) 32%-36%) and 30% (out of 1,991, 95%CI 28%-32%) of the individuals at risk had a blood pressure or lipid lowering drug prescription, respectively. In those at risk, the use of blood pressure lowering medication, increased substantially during the year of the baseline visit. Treating individuals at increased risk (≥5% 10-year risk) with lipid or blood pressure lowering medication (N = 8515 and N = 6899) would have prevented 162 and 183 CVD events, respectively, in the upcoming five years.
Conclusion: Primary prevention of CVD in the general population appears suboptimal. Feedback of cardiovascular risk factors resulted in a substantial increase of blood pressure lowering medication and extrapolated health benefits.
Keywords: Cardiovascular disease; Lifelines; Primary prevention; Risk assessment; Risk factors.
© 2020 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.Eur J Prev Cardiol. 2014 Feb;21(2):192-202. doi: 10.1177/2047487312462150. Epub 2012 Oct 2. Eur J Prev Cardiol. 2014. PMID: 23033546
-
Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative.Clin Epidemiol. 2018 Aug 16;10:981-989. doi: 10.2147/CLEP.S163037. eCollection 2018. Clin Epidemiol. 2018. PMID: 30147377 Free PMC article.
-
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.Front Pharmacol. 2020 May 8;11:624. doi: 10.3389/fphar.2020.00624. eCollection 2020. Front Pharmacol. 2020. PMID: 32457621 Free PMC article.
-
Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis.JAMA Intern Med. 2018 Jan 1;178(1):28-36. doi: 10.1001/jamainternmed.2017.6015. JAMA Intern Med. 2018. PMID: 29131895 Free PMC article.
-
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.BMJ. 2009 May 19;338:b1665. doi: 10.1136/bmj.b1665. BMJ. 2009. PMID: 19454737 Free PMC article. Review.
Cited by
-
Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study.Cardiovasc Ther. 2022 May 24;2022:6587165. doi: 10.1155/2022/6587165. eCollection 2022. Cardiovasc Ther. 2022. PMID: 35676913 Free PMC article.
References
-
- Timmis A., Townsend N., Gale C.P. European society of Cardiology: cardiovascular disease Statistics 2019. Eur. Heart J. 2020;41:12–85. - PubMed
-
- Cardoso R., Nasir K. Primary prevention of cardiovascular disease: 2019 and beyond. Nat. Rev. Cardiol. 2019;16:387–388. - PubMed
-
- Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J. Hypertens. 2014;32:2285–2295. - PubMed
-
- Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–598. - PubMed
-
- Simmons R.K., Griffin S.J., Witte D.R., Borch-Johnsen K., Lauritzen T., Sandbaek A. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia. 2017;60:2183–2191. - PMC - PubMed
LinkOut - more resources
Full Text Sources